• Citer

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

par Wilgenhof, Sofie;Du Four, Stephanie;Vandenbroucke, Frederik;Everaert, Hendrik;Salmon, Isabelle ;Lienard, Danielle ;Del Marmol, Véronique ;Neyns, Bart
Référence Journal of immunotherapy, 36, 3, page (215-222)
Publication Publié, 2013-04

Article révisé par les pairs

• Détails
• Contenu

Titre:	Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.
Auteur:	Wilgenhof, Sofie; Du Four, Stephanie; Vandenbroucke, Frederik; Everaert, Hendrik; Salmon, Isabelle; Lienard, Danielle; Del Marmol, Véronique; Neyns, Bart
Informations sur la publication:	Journal of immunotherapy, 36, 3, page (215-222)
Statut de publication:	Publié, 2013-04
Sujet CREF:	Anatomopathologie
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Antibodies, Monoclonal -- adverse effects -- therapeutic use
	Antineoplastic Agents -- adverse effects -- therapeutic use
	C-Reactive Protein -- analysis
	CTLA-4 Antigen -- immunology
	Female
	Humans
	Lymphocyte Count
	Male
	Melanoma -- drug therapy -- immunology
	Middle Aged
	Treatment Outcome
Note générale:	Journal Article
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1524-9557
	info:doi/10.1097/CJI.0b013e31828eed39
	info:pii/00002371-201304000-00007
	info:scp/84875343764
	info:pmid/23502769